UNSPSC 51171851: Ricasetron

This classification denotes a 5-ht3 receptor antagonist with the molecular formula C19H27N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R92JB88O88, chemically known as 3,3-dimethyl-n-1alphah,5alphah-tropan-3alpha-yl-1-indolinecarboxamide but generally known as ricasetron, which bears US NIH Compound Identifier 71785. European Medicines Agency schedules Ricasetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10301MIG. The term RICASETRON is an International Non-Proprietary Name.

Most nations schedule ricasetron under HS 29399900 and SITC 54149. As of Q4 2014, RICASETRON remains the US FDA Preferred Term for this commodity. Ricasetron bears US NLM identifiers UMLS ID C2699081 and NCI Concept Code C77263. SMILES: O=C(NC1CC2N(C(C1)CC2)C)N1CC(C2C1CCCC2)(C)C.

UNSPSC 51171851 Ricasetron, a Commodity code, covers pharmaceutical substances where state and local governments procure drug-testing services, therapeutic pharmacy initiatives, and generic pharmaceutical supply agreements through cooperative purchasing vehicles and direct contracting arrangements. The work being solicited spans specimen collection and drug-testing operations for criminal justice supervision, direct-to-manufacturer prescription fulfillment programs, and multi-source generic pharmaceuticals distributed through authorized wholesalers to state and local health and corrections facilities. Issuing bodies include county criminal justice departments, state health and human services commissions, and multistate cooperative purchasing alliances serving participating state agencies and local government facilities.

Recent activity spans Texas and the Upper Midwest. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services with a response deadline of July 23, 2026 and an estimated contract value of $600,000 over two years with three optional one-year renewals, requiring SAMHSA, Texas DPS, or CAP lab certification and per-test pricing covering immunoassay screening with LC/MS/MS or GC/MS confirmation across two collection sites. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, functioning as exploratory market intelligence before formal RFP issuance. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to supply through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., with evaluation weighted 75 percent on price competitiveness and 25 percent on administrative compliance and pricing flexibility.